Nothing Special   »   [go: up one dir, main page]

PA8807201A1 - Composiciones farmaceuticas - Google Patents

Composiciones farmaceuticas

Info

Publication number
PA8807201A1
PA8807201A1 PA20088807201A PA8807201A PA8807201A1 PA 8807201 A1 PA8807201 A1 PA 8807201A1 PA 20088807201 A PA20088807201 A PA 20088807201A PA 8807201 A PA8807201 A PA 8807201A PA 8807201 A1 PA8807201 A1 PA 8807201A1
Authority
PA
Panama
Prior art keywords
pharmaceutical compositions
particles
reticulated
present
patients
Prior art date
Application number
PA20088807201A
Other languages
English (en)
Inventor
J Harris David
Randall Holmes-Farley Stephen
C Polomoscanik Steven
Salameh Adnan
Shutts Bruce
Silva Richard
K Dhal Pradeep
Sole Lynne
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of PA8807201A1 publication Critical patent/PA8807201A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J41/00—Anion exchange; Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
    • B01J41/08—Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
    • B01J41/12—Macromolecular compounds
    • B01J41/14—Macromolecular compounds obtained by reactions only involving unsaturated carbon-to-carbon bonds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCION HACE REFERENCIA A PARTICULAS DE POLILAMINA RETICULADA Y/O COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN, AL MENOS EN PARTE, PARTICULAS DE POLILAMINA RETICULADAS Y AGREGADOS DE TALES PARTICULAS [ QUE INCLUYEN AGREGADOS CURADOS DE PARTICULAS DE POLILAMINA RETICULADA]. LAS COMPOSICIONES PUEDEN ESTAR PRESENTES EN LA FORMA DE COMPRIMIDOS QUE COMPRENDEN, POR EJEMPLO, PARTICULAS MAYORES QUE 500µm, Y UTILIZARSE PARA TRATAR PACIENTES, POR EJEMPLO, PACIENTES CON HIPERFOSFATEMIA.
PA20088807201A 2007-12-14 2008-12-11 Composiciones farmaceuticas PA8807201A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US601907P 2007-12-14 2007-12-14

Publications (1)

Publication Number Publication Date
PA8807201A1 true PA8807201A1 (es) 2009-07-23

Family

ID=40753579

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20088807201A PA8807201A1 (es) 2007-12-14 2008-12-11 Composiciones farmaceuticas

Country Status (9)

Country Link
US (4) US20090155368A1 (es)
EP (1) EP2222313A4 (es)
JP (1) JP2011506448A (es)
AR (1) AR072652A1 (es)
PA (1) PA8807201A1 (es)
PE (1) PE20091331A1 (es)
TW (1) TW200930384A (es)
UY (1) UY31530A (es)
WO (1) WO2009078956A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110142952A1 (en) * 2008-06-20 2011-06-16 Harris David J Pharmaceutical Compositions
WO2013064193A1 (en) * 2011-11-04 2013-05-10 Synthon Bv Pharmaceutical compositions comprising sevelamer
WO2013087237A1 (en) * 2011-12-13 2013-06-20 Synthon Bv Purification of sevelamer and related polyallylamines
RU2014128587A (ru) * 2011-12-13 2016-02-10 Синтон Б.В. Получение севеламера с пониженным содержанием аллиламина
CN102895204B (zh) * 2012-11-08 2014-12-31 南京生命能科技开发有限公司 一种用于制备片剂的碳酸司维拉姆原料药及其制备方法和应用
CN103864972A (zh) * 2012-12-10 2014-06-18 天津泰普药品科技发展有限公司 一种碳酸司维拉姆的制备方法
WO2014122586A1 (en) * 2013-02-08 2014-08-14 Wockhardt Limited Oral pharmaceutical composition of aliphatic amine polymer or salts thereof
CN111671766B (zh) 2013-06-05 2024-03-08 特里赛达公司 用于口服施用的结合质子的聚合物
PL3593808T3 (pl) 2014-12-10 2021-06-14 Tricida Inc. Polimery wiążące protony do podawania doustnego
MA41202A (fr) * 2014-12-18 2017-10-24 Genzyme Corp Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
WO2017193024A1 (en) 2016-05-06 2017-11-09 Tricida, Inc. Hcl-binding compositions for and method of treating acid-base disorders
RU2722183C1 (ru) * 2016-10-20 2020-05-28 Колгейт-Палмолив Компани Противомикробные композиции для ухода за полостью рта или ее очистки и способы получения полимеров и покрытий, препятствующих прикреплению
KR101853260B1 (ko) * 2016-11-29 2018-06-14 주식회사 퍼슨 세벨라머 카보네이트의 제조방법
KR20190084125A (ko) 2016-12-28 2019-07-15 후지필름 가부시키가이샤 질소 원자 함유 폴리머 또는 그 염의 유화액, 그 제조 방법, 및 입자의 제조 방법
CN111225674A (zh) * 2017-10-16 2020-06-02 富士胶片株式会社 高磷血症治疗剂
CA3079171C (en) * 2017-10-16 2023-09-12 Fujifilm Corporation Therapeutic agent for hyperphosphatemia and particles
CA3080651A1 (en) 2017-11-03 2019-05-09 Tricida, Inc. Compositions for and method of treating acid-base disorders
CN109125273B (zh) * 2018-09-28 2020-10-09 北京市中关村医院 一种磷结合剂及其制备方法和用途
CN112972407A (zh) * 2019-12-18 2021-06-18 南京恒生制药有限公司 一种碳酸司维拉姆片剂组合物及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW474813B (en) * 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
US6423754B1 (en) * 1997-06-18 2002-07-23 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with polyallylamine polymers
TW568788B (en) * 1998-10-12 2004-01-01 Chugai Pharmaceutical Co Ltd Polymer combining with phosphoric acid and preparation containing the same
US7608674B2 (en) * 2003-11-03 2009-10-27 Ilypsa, Inc. Pharmaceutical compositions comprising cross-linked small molecule amine polymers
HUE026628T2 (en) * 2005-09-15 2016-06-28 Genzyme Corp Pouches for amine polymers

Also Published As

Publication number Publication date
US20160158275A1 (en) 2016-06-09
EP2222313A1 (en) 2010-09-01
UY31530A (es) 2009-12-14
US20190240252A1 (en) 2019-08-08
AR072652A1 (es) 2010-09-15
JP2011506448A (ja) 2011-03-03
US20140322319A1 (en) 2014-10-30
EP2222313A4 (en) 2011-02-16
PE20091331A1 (es) 2009-09-18
WO2009078956A1 (en) 2009-06-25
US20090155368A1 (en) 2009-06-18
TW200930384A (en) 2009-07-16

Similar Documents

Publication Publication Date Title
PA8807201A1 (es) Composiciones farmaceuticas
BRPI0515592A (pt) medicamentos compreendendo compostos de carbonila, e o uso dos mesmos
BRPI0705488A (pt) composição nanoparticulada estável, métodos de preparar a mesma e de prevenir e/ou tratar uma infecção bacteriana, composição farmacêutica, e, forma de dosagem
CR9949A (es) Inhibidores de proteina activadora de la 5-lipoxigenasa (flap)
BR112015014372A2 (pt) inibidores de autotaxina
BR112012010706A2 (pt) composto, composição farmacêutica, combinação do produto farmacêutico, uso de um composto, e, métodos para o tratamento de uma doença ou condição, e para inibir um bromodomínio
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
BR112015011171A2 (pt) compostos de pirrolopirimidina como inibidores da quinase
GT200900057A (es) 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluorofenoxi]-n-metilpiridina-2-carboxamida monohidrato
BR112015001955A2 (pt) variante de região fc específica de fcgamariib
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
BR112015011403A2 (pt) uso de akkermansia para o tratamento de distúrbios metabólicos
BR112015007814A2 (pt) diagnóstico, prevenção e tratamento de doenças da articulação
UY28931A1 (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
BR112015000320A2 (pt) composições farmacêuticas dissuasivas de abuso, de liberação prolongada
CR9955A (es) Tipo de brocoli que tiene inflorescencia con flosculos separados
CL2011002130A1 (es) Uso de una composicion que comprende una mezcla fisica o combinacion de polvos, granulos, cristales o agregados de sales de calcio, magnecio y hierro para el tratamiento de enfermedades relacionadas con la absorcion alterada de fosforo en seres humanos y animales.
CL2013001482A1 (es) Compuestos derivados de 3-metil-7-oxo-4-tia-1-aza-biciclo[3.2.0]heptano para utilizarse en la inhibicion de beta-lactamasas producidas por bacterias y restaurar/potenciar la actividad de antibioticos; y composicion farmaceutica que los comprende.
BRPI0914907A8 (pt) Composição particulada para ração e ração
CL2013003630A1 (es) Formulacion farmaceutica liquida que comprende nitisinona y un tampon de acido citrico que tien un ph en el rango de 2,5 a 3,5, de preferencia 3,0; y su uso para el tratamiento de tirosemia, enfermedad de parkinson, depresion, entre otros.
BRPI0917956A2 (pt) formulação farmacêutica veterinária que inclui uma partícula recombinante de rna que codifica para uma proteína cu/zn superóxido dismutase de bactérias patogênicas de ruminantes e pelo menos um alfavírus rna pertencente à família do vírus semliki forest
CL2008003799A1 (es) Composicion farmaceutica que comprende raloxifeno en forma de tableta de liberacion inmediata; util para el tratamiento y/o prevencion de la osteoporosis.
CO7131387A2 (es) Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido
BR112014012277A2 (pt) composição farmacêutica para tratamento de reações alérgicas
UY29417A1 (es) Agentes endoparasiticidas